PGxAI Selected as a Finalist at the HLTH USA 2025 Startup Pitch Tournament
Events | Published: Nov 14, 2025
PGxAI was selected as a finalist in the HLTH USA 2025 Startup Pitch Tournament within the Specialty Care category. From hundreds of applications, only eight companies were chosen to showcase leading innovations shaping the future of clinical care. Presenting on the Specialty Care stage highlighted the growing interest in PGxAI’s multi-omics and AI-driven precision medicine technologies.
HLTH USA is one of the largest and most influential healthcare conferences globally, bringing together leaders from health systems, research institutions, payors, life sciences, venture capital, and regulatory agencies. It serves as a premier platform where industry-defining trends are announced and next-generation technologies are introduced.
We appreciate the recognition of PGxAI’s contribution to advancing data-driven precision medicine. Participation in HLTH further strengthens our international visibility and underscores the importance of our methodologies for addressing complex clinical challenges.
About PGxAI
PGxAI is advancing precision medicine by addressing drug selection and dosage optimization with unmatched accuracy and reproducibility. By integrating artificial intelligence, multiomics, and real-world evidence, the company enables clinicians and health systems to deliver safer, more effective, and personalized therapies.
Founded by Mike Zack, MD, PhD, MPH — a pharmacogenomics scientist ranked among the world’s top 1% by citations (Elsevier 2025) — and Allan Gobbs, a life sciences entrepreneur with nine exits including five IPOs, PGxAI collaborates with leading partners such as Google Cloud, Microsoft, Nvidia, AWS, InterSystems, MIT (MIMIC-IV), NIH (All of Us), UF Health, the University of British Columbia, and the Ministries of Sport and Health of Saudi Arabia.
Its advisory board includes global leaders in precision medicine, including Russ Altman (Stanford University), Bruce Broussard (former CEO, Humana), John Quackenbush (Harvard T.H. Chan School of Public Health & Dana-Farber Cancer Institute), and David Blumenthal (former U.S. National Coordinator for Health IT and past President of The Commonwealth Fund), alongside senior affiliates from Thermo Fisher, Quest Diagnostics, and Abbott.
PGxAI is pioneering ultra-precision medicine and setting new standards in AI-powered pharmacogenomics worldwide.
